Analysis of STEP clinical trials shows semaglutide more than halves risk of T2DM
The risk of type 2 diabetes mellitus (T2DM) is more than halved by weekly injections of new obesity drug semaglutide, according to...
top of page
Browse by category
Search
STEP outcomes: Semaglutide could be ‘gamechanger’ in battle against obesity
One third (35%) of patients who received semaglutide for treating obesity lost more than one-fifth (greater than or equal to 20%) of...
Browse by tag
bottom of page